Dal-Bianco P, Maly J, Wôber C, Lind C, Koch G, Hufgard J, Marschall I, Mraz M, Deecke L
Neurology University Clinic, Vienna, Austria.
J Neural Transm Suppl. 1991;33:59-63. doi: 10.1007/978-3-7091-9135-4_10.
18 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.
18名符合NINCDS-ADRDA“可能的阿尔茨海默病”标准的患者参与了一项临床研究，以评估胆碱酯酶抑制剂加兰他敏（每日30毫克）的效果。对神经心理学和社会参数进行了评估。这项开放性临床试点研究表明，神经心理学测试结果没有统计学上的显著变化。然而，经过1年的治疗，仍有6名患者在服用该药物。据他们的护理人员称，日常生活能力和/或情绪状况有积极变化。
